Market Intelligence, Clinical Progress, and High-Purity Reagents for Sepsis, ARDS, Amyloidosis, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GSN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Plasma) | Human Plasma Gelsolin (pGSN) Recombinant Protein Secreted isoform (aa 1-782), Actin-binding domains intact, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed (native glycosylation). |
View GSN Products |
| Antigen (Cytoplasmic) | Human Cytoplasmic Gelsolin (cGSN) Recombinant Protein Intracellular isoform (aa 1-782, unique N-term), Theoretical MW verified. Suitable for intracellular targeting assays. |
View GSN Products |
| Mutant Control | Gelsolin G167R Mutant (Actin-binding deficient) Negative control for binding assays. Sequence Verified. Critical for mechanism-of-action studies. |
View GSN Products |
| Gene Delivery | GSN Promise-ORF / Lentivirus Full-length ORF for stable cell lines and rescue experiments. |
View GSN Products |
| Benchmark Ab | Anti-GSN Recombinant Monoclonal Antibody Sequence-verified positive control for Western Blot, IHC, and Flow Cytometry. |
View GSN Products |
| Validator | GSN siRNA Set For knockdown verification and specificity controls. |
View GSN Products |
| Related Target A | ACTB (Beta-Actin) Primary interacting partner (Actin scavenging pathway) |
View ACTB Products |
| Related Target B | CFL1 (Cofilin-1) Actin-binding partner in cytoskeletal remodeling; synergistic pathway for metastasis research. |
View CFL1 Products |
| Related Target C | TLR4 Synergistic target in severe inflammation/sepsis |
View TLR4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Specificity (Plasma vs Cytoplasmic) | Distinct N-terminal sequences preserved: Plasma form includes signal peptide (aa 1-28) processed during secretion vs Cytoplasmic specific N-term. Both isoforms sequence-verified by Mass Spec. |
| Amyloidogenic Mutant Validation | Disease-associated mutant proteins (e.g., D187N, D187Y) provided with theoretical MW and high purity. |
| Actin-binding Functional Fidelity | Native conformation maintained via HEK293 expression system. High-purity protein suitable for G-actin/F-actin cosedimentation assays and SPR kinetic analysis. |
| Cross-species Preclinical Translation (cyno / mouse) | Human / Mouse / Cyno ortholog recombinant proteins available with matched purity specs. |
| Lack of Controls / False Positives | Clinical Benchmark Antibodies (Biosimilars) included; Validated siRNA included for specificity checks; G167R Actin-binding deficient mutant included as rigorous negative control. |
Live GSN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Gelsolin (GSN) therapeutics is intensifying, focusing on two distinct therapeutic avenues: protein replacement therapy for severe systemic inflammation (like ARDS and sepsis) where plasma gelsolin is rapidly depleted, and targeted therapies for Gelsolin Amyloidosis (FAF). As first-generation recombinant plasma gelsolin (rhu-pGSN) therapies reach the clinic, the next wave of R&D is targeting optimal isoform delivery and mutant-specific clearance antibodies. On the oncology front, preclinical programs are pursuing small-molecule and biologic inhibitors of intracellular gelsolin to suppress actin-severing activity and reduce metastatic potential. As first-generation biologics approach inflection points in inflammatory indications, the next wave of R&D is targeting rare disease mutations—specifically the D187N and D187Y variants responsible for familial amyloidosis of Finnish type (FAF)—and expanding into combination regimens for solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein | BioAegis Therapeutics | ARDS, Sepsis, Severe Trauma, COVID-19 | Actin-binding capacity (Need high-purity GSN) |
| Monoclonal Antibodies | Early Stage/Academic | Gelsolin Amyloidosis (FAF) | Mutant Specificity (Need Mutant vs WT Proteins) |
| Small Molecules | Various Biotech | Amyloid Fibril Inhibition, Metastatic Solid Tumors | Fibrillization Assay (Need High Purity Mutant GSN) |
| siRNA / Gene Therapy | Preclinical Developers | Oncology | Knockdown validation (Need validated GSN siRNA and Lentivirus rescue controls) |
Molecular Differentiation & Assay Strategy
Functional Fidelity
For replacement therapy, recombinant pGSN must retain native conformation to effectively scavenge circulating actin. The gold-standard assay is the Pyrene-actin polymerization/depolymerization experiment, measuring severing and capping kinetics. TarMart provides HEK293-expressed, high-purity (>95%), sequence-verified WT GSN protein for such assays.
Mutant Selectivity
For FAF therapy, molecules must distinguish WT GSN from D187N/Y mutants. Assay strategy involves differential binding SPR or DSF screening using both WT and mutant proteins. TarMart offers sequence-verified mutant proteins (D187N, D187Y) from the same expression system for direct comparison.
Isoform Selectivity
Plasma (pGSN) and cytoplasmic (cGSN) isoforms differ only in N-terminal sequences but have distinct functions. Oncology targeting requires sparing cytoplasmic functions. Assay strategy uses isoform-specific ELISA and immunofluorescence. TarMart provides both isoforms with distinct N-termini for selective antibody screening.
Cross-species Translation
Preclinical studies require human, cyno, and mouse orthologs. TarMart's multi-species recombinant protein panel (>95% purity, endotoxin controlled) supports cross-reactivity screening.
Intracellular Validation
For oncology, phenotype must be confirmed as GSN-specific. Use TarMart GSN siRNA Set for knockdown, combined with TarMart GSN Promise-ORF / Lentivirus for rescue experiments.
Related Targets Recommendation
- ACTB (Beta-Actin): Direct substrate of GSN; essential for Pyrene-actin assays and SPR binding studies. Recommended as a binding pair kit.
- CFL1 (Cofilin-1): Another actin-severing protein; often co-regulated with GSN in cancer and neurodegeneration. Useful for counter-screening panels.
- TLR4: Key receptor in inflammatory pathways; synergistic with GSN in sepsis models.
- S100A9: Inflammatory pathway marker; relevant to plasma gelsolin sepsis models.
- PFN1 (Profilin-1): Competitive actin binder; often inversely correlated with GSN expression in cancer.